Skip to main content
Advertisement
Advertisement
PTCT
PTCT logo
PTC Therapeutics, Inc.
60.97
USD
Sponsored
-2.52
-3.97%
Nov 16, 15:59 UTC -5
Closed
exchange

Pre-Market

60.37

-0.60
-0.98%

PTC Therapeutics, Inc. (PTCT) Earnings

PTCT Earnings Reports

Positive Surprise Ratio

PTCT beat 16 of 44 last estimates.

36%

Next Report

Date of Next Report
Feb 17, 2027
Estimate for Q4 26 (Revenue/ EPS)
$336.93M
/
$0.39
Implied change from Q3 26 (Revenue/ EPS)
-5.83%
/
-162.90%
Implied change from Q4 25 (Revenue/ EPS)
+58.04%
/
-123.35%

PTC Therapeutics, Inc. earnings per share and revenue

On Oct 29, 2026, PTCT reported earnings of -0.62 USD per share (EPS) for Q3 26, missing the estimate of 0.34 USD, resulting in a -277.96% surprise. Revenue reached 357.81 million, compared to an expected 312.53 million, with a 14.49% difference. The market reacted with a -6.97% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 9 analysts forecast an EPS of 0.39 USD, with revenue projected to reach 336.93 million USD, implying an decrease of -162.90% EPS, and decrease of -5.83% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Enanta Pharmaceuticals, Inc
Report Date
Nov 16, 2026 For Q4 26
Estimate
-$0.79
Actual
-$0.81
Surprise
-1.38%
logo
Genelux Corporation Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.22%
logo
Neumora Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.20
Actual
-$0.18
Surprise
+10.54%
logo
Eloxx Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.58
Actual
-$0.49
Surprise
+16.70%
logo
Rein Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%
logo
Connect Biopharma Holdings Limited Ordinary Shares
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+4.59%
logo
Instil Bio, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.17
Actual
-$0.62
Surprise
-261.09%
logo
Estrella Immunopharma, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.17
Surprise
-108.33%
logo
Jasper Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$3.02
Actual
-$13.97
Surprise
-361.93%
logo
Kyntra Bio, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$3.61
Actual
-$3.42
Surprise
+5.49%
FAQ
For Q3 2026, PTC Therapeutics, Inc. reported EPS of -$0.62, missing estimates by -277.96%, and revenue of $357.81M, 14.49% above expectations.
The stock price moved down -6.97%, changed from $64.46 before the earnings release to $59.97 the day after.
The next earning report is scheduled for Feb 17, 2027.
Based on 9 analysts, PTC Therapeutics, Inc. is expected to report EPS of $0.39 and revenue of $336.93M for Q4 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement